Hypnogen

Zolpidem, the active ingredient in Hypnogen, is an imidazopyridine (non‑benzodiazepine hypnotic) presented as an oral tablet for oral administration. It is indicated for the short‑term treatment of insomnia in adults, helping to initiate and maintain sleep when prescribed by a qualified healthcare professional. The medication works by enhancing the activity of the inhibitory neurotransmitter GABA, thereby promoting sleep onset and continuity. It is supplied in compliance with EU pharmaceutical standards and requires a prescription.

GNH USA supplies Hypnogen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Zolpidem is used to treat sleep disorders by acting on the central nervous system to facilitate sleep initiation.

- Insomnia (short‑term): improves sleep onset and maintenance in adults - Sleep onset difficulty: reduces time needed to fall asleep - Sleep maintenance difficulty: decreases nighttime awakenings

Common side effects are generally mild and transient.

Common Side Effects: - Drowsiness or fatigue - Dizziness or light‑headedness - Headache - Nausea or dry mouth - Amnesia or memory impairment

Serious or Rare Side Effects: - Complex sleep behaviors (e.g., sleep‑walking, sleep‑driving) - Allergic reactions (rash, swelling, difficulty breathing) - Mood changes or depression

Before prescribing Zolpidem, consider the following precautions: - Assess sleep disorder duration: limit use to short‑term therapy - Avoid alcohol: may enhance central nervous system depression - Caution in hepatic impairment: adjust use if necessary - Monitor for complex sleep behaviors: advise patients to report unusual activities - Store at ambient temperature: keep in original container, protect from moisture

Zolpidem may interact with other substances that affect the central nervous system or its metabolism.

Major Interactions (Avoid): - Alcohol: additive CNS depression - Strong CYP3A4 inhibitors (e.g., ketoconazole): increased zolpidem exposure - Other CNS depressants (opioids, benzodiazepines): risk of profound sedation

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): reduced efficacy - Certain antidepressants (e.g., fluoxetine): possible increased sedation - Antihistamines: additive drowsiness